Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mizoribine plus steroid vs cyclophosphamide plus steroid in membranous nephropathy
ChiCTR-IPR-17011702Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in membranous glomerulonephritis (MGN) comparing mizoribine + steroid with cyclophosphamide + steroid (2 arms). Primary endpoints: Total remission rate, Complete remission rate and 1 more. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
mizoribinecyclophosphamide
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on ChiCTR-IPR-17011702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011702.